HomeCONGRESSInternational Congresses

International Congresses

View Category
Day 3

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus...
solaci -
Learn More
Day 3

VELOCITY: Peritoneal hypothermia in patients undergoing primary angioplasty

There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal...
solaci -
Learn More
Day 3

TRANSLATE-ACS: One-year prasugrel versus clopidogrel after acute coronary syndrome

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute...
solaci -
Learn More
Day 3

ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination...
solaci -
Learn More
Day 3

BRIGHT: Bivalirudin versus heparin versus heparin plus tirofiban in primary angioplasty

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB...
solaci -
Learn More
Day 1

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the...
solaci -
Learn More
Day 1

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times...
solaci -
Learn More
Day 1

PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment....
solaci -
Learn More